Minerva Neurosciences, INC. (NERV) — SEC Filings

Q: What are the key financial highlights for Minerva Neurosciences, INC.?

Key financial highlights for Minerva Neurosciences, INC. are extracted from the most recent 10-K or 10-Q filings, including revenue, net income, EPS, debt-to-equity, cash position, and operating margin.

Q: Who are the key executives at Minerva Neurosciences, INC.?

Key executives at Minerva Neurosciences, INC. are identified from SEC filings including 10-K annual reports, proxy statements, and insider trade forms.

Q: What are the main risk factors for Minerva Neurosciences, INC. stock?

Risk factors for Minerva Neurosciences, INC. (NERV) are assessed from SEC filings using AI analysis. Each filing is categorized as high, medium, or low risk based on disclosed risk factors and financial indicators.

Q: What are recent predictions and forward guidance from Minerva Neurosciences, INC.?

Forward-looking statements and predictions from Minerva Neurosciences, INC. are extracted from SEC filings including earnings reports, annual reports, and current event filings.

Latest SEC filings for Minerva Neurosciences, INC.. Recent ARS filing on Apr 23, 2026. AI-decoded analysis of earnings, risk factors, and insider trades.

View Minerva Neurosciences, INC. on SEC EDGAR

Overview

Minerva Neurosciences, INC. (NERV) is a publicly traded company tracked on ReadTheFiling. The most recent enriched filing is a ARS filed on Apr 23, 2026: Minerva Neurosciences, Inc. filed its Annual Report to Security Holders (ARS) on April 23, 2026, for the period ending December 31, 2025. The company, located at 1500 District Avenue, Burlington, MA, is involved in the pharmaceutical preparations industry. This filing provides a comprehensive overvi

Sentiment Summary

Across 30 filings, the sentiment breakdown is: 2 bullish, 5 bearish, 23 neutral. The dominant filing sentiment for Minerva Neurosciences, INC. is neutral.

Filing Type Overview

Minerva Neurosciences, INC. (NERV) has filed 1 ARS, 1 DEFA14A, 11 8-K, 2 DEF 14A, 6 10-Q, 4 10-K/A, 2 10-K, 2 SC 13G/A, 1 SC 13G with the SEC between Jan 2024 to Apr 2026.

Filings by Year

2026 · 2025 · 2024

Recent Filings (30)

Minerva Neurosciences Files Annual Report — ARS · Apr 23, 2026 Risk: medium
Minerva Neurosciences, Inc. filed its Annual Report to Security Holders (ARS) on April 23, 2026, for the period ending December 31, 2025. The company, located a
DEFA14A Filing — DEFA14A · Apr 23, 2026
8-K Filing — 8-K · Dec 22, 2025
Minerva Neurosciences Seeks to Double Authorized Shares, Boost Equity Plan — DEF 14A · Nov 24, 2025 Risk: high
Minerva Neurosciences, Inc. (NERV) is holding its 2025 Annual Meeting on December 22, 2025, virtually, to address several critical proposals impacting its corpo
Minerva Neurosciences Reports Director/Officer Changes & Compensation — 8-K · Nov 19, 2025 Risk: medium
Minerva Neurosciences, Inc. filed an 8-K on November 19, 2025, reporting events as of November 14, 2025. The filing indicates a departure of directors or certai
Minerva Swings to $9.76M Loss, Secures $80M for Roluperidone Trial — 10-Q · Nov 5, 2025 Risk: high
Minerva Neurosciences, Inc. (NERV) reported a significant net loss of $9.76 million for the nine months ended September 30, 2025, a stark contrast to the net in
Minerva Neurosciences Files 8-K with Key Corporate Updates — 8-K · Oct 22, 2025 Risk: medium
Minerva Neurosciences, Inc. filed an 8-K on October 22, 2025, reporting on events as of October 21, 2025. The filing indicates entry into a material definitive
NERV's Losses Narrow Amid R&D Cuts, But Liquidity Concerns Mount — 10-Q · Aug 14, 2025 Risk: high
Minerva Neurosciences, Inc. (NERV) reported a net loss of $3.26 million for the three months ended June 30, 2025, a significant improvement from the $8.23 milli
Minerva Neurosciences Files Q1 2025 10-Q — 10-Q · May 13, 2025 Risk: medium
Minerva Neurosciences, Inc. filed its 10-Q for the period ending March 31, 2025. The company's primary focus is on the development of pharmaceutical preparation
Minerva Neurosciences Files 2024 10-K Amendment — 10-K/A · Apr 29, 2025 Risk: low
Minerva Neurosciences, Inc. filed an amendment (No. 2) to its 2024 10-K report on April 29, 2025. The company, incorporated in Delaware with its principal execu
Minerva Neurosciences Files 2024 Annual Report Amendment — 10-K/A · Apr 21, 2025 Risk: medium
Minerva Neurosciences, Inc. filed an amendment (10-K/A) on April 21, 2025, for its fiscal year ended December 31, 2024. The company, incorporated in Delaware an
Minerva Neurosciences Files 8-K — 8-K · Mar 19, 2025 Risk: low
Minerva Neurosciences, Inc. filed an 8-K on March 19, 2025, reporting an event that occurred on March 17, 2025. The filing is categorized under 'Other Events' a
Minerva Neurosciences Files 2024 10-K — 10-K · Feb 25, 2025 Risk: medium
Minerva Neurosciences, Inc. filed its 2024 10-K on February 25, 2025, reporting on its fiscal year ending December 31, 2024. The company, focused on pharmaceuti
Sosei to Acquire Minerva Neurosciences for $1.5B — 8-K · Jan 13, 2025 Risk: medium
Minerva Neurosciences, Inc. announced on January 10, 2025, that it has entered into a definitive agreement to be acquired by Sosei Group Corporation for approxi
Minerva Neurosciences Files 8-K on Shareholder Votes — 8-K · Dec 5, 2024 Risk: low
Minerva Neurosciences, Inc. filed an 8-K on December 5, 2024, to report on matters submitted to a vote of its security holders. The filing details the company's
SC 13G/A Filing — SC 13G/A · Nov 12, 2024
Minerva Neurosciences Files Q3 2024 10-Q — 10-Q · Nov 5, 2024 Risk: medium
Minerva Neurosciences, Inc. filed its 10-Q for the period ending September 30, 2024. The company's financial statements reflect its ongoing operations in the ph
Minerva Neurosciences Files Definitive Proxy Statement — DEF 14A · Oct 22, 2024 Risk: low
Minerva Neurosciences, Inc. filed its definitive proxy statement (DEF 14A) on October 22, 2024, for its annual meeting of stockholders. The filing provides deta
Minerva Neurosciences Faces Delisting Concerns — 8-K · Oct 11, 2024 Risk: high
Minerva Neurosciences, Inc. filed an 8-K on October 11, 2024, to report a notice of delisting or failure to satisfy a continued listing rule or standard. The co
Minerva Neurosciences Files 8-K — 8-K · Sep 16, 2024 Risk: medium
Minerva Neurosciences, Inc. filed an 8-K on September 16, 2024, reporting an "Other Event" as of September 14, 2024. The filing does not contain specific detail
Minerva Neurosciences Files Q2 2024 10-Q — 10-Q · Aug 6, 2024 Risk: medium
Minerva Neurosciences, Inc. filed its 10-Q for the period ending June 30, 2024. The company reported research and development expenses for the six months ended
Minerva Neurosciences Announces Board and Executive Changes — 8-K · May 30, 2024 Risk: medium
Minerva Neurosciences, Inc. announced on May 29, 2024, changes in its board of directors and executive compensation. Dr. Jonathan F. Miller has been appointed a
Minerva Neurosciences Files 10-Q for Period Ending March 31, 2024 — 10-Q · May 1, 2024 Risk: medium
Minerva Neurosciences, Inc. (NERV) filed a Quarterly Report (10-Q) with the SEC on May 1, 2024. Minerva Neurosciences, Inc. filed a 10-Q report for the period e
Minerva Neurosciences Files Amended 10-K for Fiscal Year Ended Dec 31, 2023 — 10-K/A · Apr 22, 2024 Risk: low
Minerva Neurosciences, Inc. (NERV) filed a Amended Annual Report (10-K/A) with the SEC on April 22, 2024. Minerva Neurosciences, Inc. filed an amended 10-K repo
Minerva Neurosciences Faces Nasdaq Delisting Warning — 8-K · Apr 12, 2024 Risk: high
Minerva Neurosciences, Inc. announced on April 10, 2024, that it received a notice from Nasdaq regarding its failure to meet the minimum bid price requirement f
Minerva Neurosciences Files 8-K for Other Events & Exhibits — 8-K · Feb 27, 2024 Risk: low
Minerva Neurosciences, Inc. filed an 8-K on February 27, 2024, reporting an event that occurred on February 26, 2024. The filing indicates 'Other Events' and 'F
Minerva Neurosciences Files Amended 10-K for Fiscal Year Ended December 31, 2023 — 10-K/A · Feb 26, 2024 Risk: low
Minerva Neurosciences, Inc. (NERV) filed a Amended Annual Report (10-K/A) with the SEC on February 26, 2024. Minerva Neurosciences, Inc. filed an amended 10-K r
Minerva Neurosciences Files 2023 Annual Report on Form 10-K — 10-K · Feb 22, 2024 Risk: medium
Minerva Neurosciences, Inc. (NERV) filed a Annual Report (10-K) with the SEC on February 22, 2024. Minerva Neurosciences, Inc. filed its 2023 Form 10-K on Febru
FMR LLC Discloses 7.031% Passive Stake in Minerva Neurosciences — SC 13G · Feb 9, 2024 Risk: low
FMR LLC, a major investment management firm, and its Chair and CEO, Abigail P. Johnson, have disclosed a significant passive stake in Minerva Neurosciences, Inc
Federated Hermes Amends Minerva Neurosciences Stake (13G/A) — SC 13G/A · Jan 18, 2024
Federated Hermes, Inc. filed an amended Schedule 13G/A on January 18, 2024, indicating a change in their beneficial ownership of Minerva Neurosciences, Inc. com

Risk Profile

Risk Assessment: Of NERV's 26 recent filings, 5 were flagged as high-risk, 13 as medium-risk, and 8 as low-risk. The overall risk profile suggests moderate risk with a balanced mix of positive and cautionary disclosures.

Financial Highlights

Key financial metrics from Minerva Neurosciences, INC.'s most recent 10-Q filing (Nov 5, 2025):

Revenue: N/A
Net Income: -$9.76M
EPS: N/A
Debt-to-Equity: N/A
Cash Position: $12.29M
Operating Margin: N/A
Total Assets: N/A
Total Debt: N/A

Key Executives

Fouzia Laghrissi-Thode
Inderjit Kaul
Frederick Ahlholm
Dr. Jonathan F. Miller
Dr. Alted
Abigail P. Johnson

Industry Context

Minerva Neurosciences operates in the biopharmaceutical sector, focusing on developing treatments for central nervous system disorders. This industry is characterized by high R&D costs, long development timelines, and significant regulatory hurdles. Companies in this space often rely on substantial capital raises to fund clinical trials and operations, making stock authorization proposals critical for future flexibility.

Top Tags

pharmaceuticals (4) · 10-Q (4) · financials (4) · Minerva Neurosciences (4) · SEC Filing (4) · annual-report (3) · sec-filing (3) · corporate-governance (3) · amendment (3) · pharmaceutical (3)

Key Numbers

Fiscal Year End: 2025-12-31 — Period covered by the annual report
Filing Date: 2026-04-23 — Date the ARS was accepted by the SEC
Proposed total authorized common stock: 250,000,000 shares — Increase from 125,000,000 shares, representing a 100% increase
Increase in shares for 2013 Equity Incentive Plan: 12,500,000 shares — Additional shares authorized for employee compensation
Current total authorized common stock: 125,000,000 shares — Baseline before proposed amendment
Common Stock outstanding: 6,993,406 shares — As of Record Date October 23, 2025, entitled to vote
Series A Preferred Stock outstanding (as-converted): 1,391,674 shares — As of Record Date October 23, 2025, entitled to vote on an as-converted basis
Maximum Percentage: 9.99% — Beneficial ownership limit for Series A Preferred Stock conversion
Cap on Series A Preferred Stock voting: 19.9% — Percentage of outstanding Common Stock for voting calculation prior to Proposal 3 approval
Annual Meeting Date: December 22, 2025 — Date of the virtual Annual Meeting
Record Date: October 23, 2025 — Date for determining stockholders entitled to vote
Net Loss: $9.76M — for the nine months ended September 30, 2025, compared to $5.71M net income in 2024
Research and Development Expenses: $3.59M — decreased by 63.8% from $9.92M in 2024
General and Administrative Expenses: $6.54M — decreased by 11.8% from $7.41M in 2024
Cash and Cash Equivalents: $12.29M — as of September 30, 2025, down from $21.36M at December 31, 2024

Forward-Looking Statements

{"claim":"Minerva Neurosciences' stock price may experience a slight positive bump due to increased institutional investor confidence.","entity":"Minerva Neurosciences, Inc.","targetDate":"Within 1-3 months","confidence":"medium"}

Related Companies

MINV · NRNE

Frequently Asked Questions

What are the latest SEC filings for Minerva Neurosciences, INC. (NERV)?

Minerva Neurosciences, INC. has 30 recent SEC filings from Jan 2024 to Apr 2026, including 11 8-K, 6 10-Q, 4 10-K/A. Each filing includes an AI-generated plain-English summary.

What is the overall sentiment of NERV filings?

Across 30 filings, the sentiment breakdown is: 2 bullish, 5 bearish, 23 neutral. The dominant sentiment is neutral.

Where can I find Minerva Neurosciences, INC. SEC filings explained simply?

ReadTheFiling provides AI-powered plain-English summaries of all Minerva Neurosciences, INC. (NERV) SEC filings, including 10-K annual reports, 10-Q quarterly reports, 8-K current reports, and insider trades.

What are the key financial highlights for Minerva Neurosciences, INC.?

Key financial highlights from Minerva Neurosciences, INC.'s most recent 10-Q include metrics such as revenue, net income, EPS, and debt ratios. Visit the filing detail page for the full breakdown.

What is the investment thesis for NERV?

The investment thesis for NERV includes bull, base, and bear case scenarios derived from AI analysis of recent SEC filings.

Who are the key executives at Minerva Neurosciences, INC.?

Key executives identified across Minerva Neurosciences, INC.'s filings include Fouzia Laghrissi-Thode, Inderjit Kaul, Frederick Ahlholm, Dr. Jonathan F. Miller, Dr. Alted and 1 others.

What are the main risk factors for Minerva Neurosciences, INC. stock?

Of NERV's 26 assessed filings, 5 were flagged high-risk, 13 medium-risk, and 8 low-risk.

What are recent predictions and forward guidance from Minerva Neurosciences, INC.?

Recent forward-looking statements from Minerva Neurosciences, INC. include guidance on {"claim":"Minerva Neurosciences' stock price may experience a slight positive bump due to increased institutional invest.